Boorsma EM, Beusekamp JC, ter Maaten JM, et al. - By performing this predefined sub‐study of a double‐blind, randomized, placebo‐controlled, multicenter study (EMPA‐RESPONSE‐AHF), researchers investigated how empagliflozin could impact renal sodium as well as glucose handling in patients suffering from acute heart failure (HF). Within 24 hours of an acute HF admission, the patients were assigned to either empagliflozin 10 mg/day (n = 40) or placebo (n = 39) for 30 days. During the first 96 hours and at day 30, markers of glucose as well as sodium handling were assessed daily. Empagliflozin was shown to result in an increase in fractional glucose excretion as well as plasma osmolality, without impacting fractional sodium excretion or urine osmolality and also led to a temporary reduction in eGFR in patients suffering from acute HF. This indicates that in patients with acute HF, empagliflozin causes stimulation of osmotic diuresis via elevated glycosuria rather than natriuresis.